KPAX002-1: Parkinson's Disease

Phase 2 ready. K-PAX Pharmaceuticals is seeking strategic investors or a co-development partner to assist us in fully completing our Phase 2 program and developing this breakthrough therapy into the first approved disease-modifying treatment for Parkinson's disease.

KPAX002-2: Alzheimer's Disease

Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment for impaired cognitive symptoms and apathy in Alzheimer's disease.

KPAX002-3:  Amyotrophic Lateral Sclerosis (ALS) 

Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment to slow the progression of Amyotrophic lateral sclerosis (ALS).

Questions regarding partnering opportunities can be directed to K-PAX Pharmaceuticals' Director of Operations, Anne Lahaderne at: This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling (415) 381-7655.